Dermatologic drug reactions

被引:31
作者
McKenna, JK [1 ]
Leiferman, KM [1 ]
机构
[1] Univ Utah, Sch Med 4B454, Dept Dermatol, Salt Lake City, UT 84132 USA
关键词
D O I
10.1016/j.iac.2004.03.007
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Adverse reactions to medications are estimated to occur in 0.1% to 1% of patients using systemic medications. Certain medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and anticonvulsants, have drug eruption rates approaching 1% to 5% [1]. Approximately 30 drug-related cutaneous reaction patterns are described (Box 1) [2]. In addition, the same medication may evoke a different reaction pattern in different individuals. This fact makes identification of the offending agent difficult for primary care physicians, allergists, and dermatologists. An estimated 2% of medication-related skin eruptions meet the World Health Organization definition of a serious reaction [3]. Of these reactions, several constitute truly life-threatening emergencies and need rapid accurate diagnosis and intervention. This review describes common, serious, and distinctive drug reaction patterns in skin. The pathogenesis of drug allergy is discussed with respect to immunologic mechanisms; nonimmunologic drug reactions may also occur. Basic classification of skin lesions is reviewed; however, this discussion centers on identification of the most common or serious cutaneous reaction patterns.
引用
收藏
页码:399 / +
页数:26
相关论文
共 70 条
[41]  
Nigen Simon, 2003, J Drugs Dermatol, V2, P278
[42]   Specific site involvement in fixed drug eruption [J].
Özkaya-Bayazit, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 49 (06) :1003-1007
[43]   A Multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century [J].
Palmieri, TL ;
Greenhalgh, DG ;
Saffle, JR ;
Spence, PJ ;
Peck, MD ;
Jeng, JC ;
Mozingo, DW ;
Yowler, CJ ;
Sheridan, RL ;
Ahrenholz, DH ;
Caruso, DM ;
Foster, KN ;
Kagan, RJ ;
Voigt, DW ;
Purdue, GF ;
Hunt, JL ;
Wolf, S ;
Molitor, F .
JOURNAL OF BURN CARE & REHABILITATION, 2002, 23 (02) :87-96
[44]   Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity [J].
Park, BK ;
Kitteringham, NR ;
Powell, H ;
Pirmohamed, M .
TOXICOLOGY, 2000, 153 (1-3) :39-60
[45]   Drug-induced linear IgA disease: Target antigens are heterogeneous [J].
Paul, C ;
Wolkenstein, P ;
Prost, C ;
Caux, F ;
Rostoker, G ;
Heller, M ;
Wechsler, J ;
Revuz, J ;
Roujeau, JC .
BRITISH JOURNAL OF DERMATOLOGY, 1997, 136 (03) :406-411
[46]   GENETIC SUSCEPTIBILITY TO FIXED DRUG ERUPTION - EVIDENCE FOR A LINK WITH HLA-B22 [J].
PELLICANO, R ;
CIAVARELLA, G ;
LOMUTO, M ;
DIGIORGIO, G .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1994, 30 (01) :52-54
[47]  
PELLICANO R, 1992, ACTA DERM-VENEREOL, V72, P292
[48]   Delayed drug hypersensitivity reactions [J].
Pichler, WJ .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (08) :683-693
[49]   Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins - Multicenter retrospective analysis of 48 consecutive cases [J].
Prins, C ;
Kerdel, FA ;
Padilla, RS ;
Hunziker, T ;
Chimenti, S ;
Viard, I ;
Mauri, DN ;
Flynn, K ;
Trent, J ;
Margolis, DJ ;
Saurat, JH ;
French, LE .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :26-32
[50]  
REQUENA L, 2002, DERMATOL ONLINE J, V8, P1